A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus
nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose (MTD) for
unresectable locally advanced pancreatic adenocarcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Osaka Medical Center for Cancer and Cardiovascular Diseases